COGSTATE LTD — Regulatory Filings 2008

Jun 12, 2008

==> picture [235 x 49] intentionally omitted <==

CogState Ltd ABN 80 090 975 723 Level 7 21 Victoria Street Melbourne Vic 3000 Australia

ASX Announcement

Melbourne, 13[th] June 2008

CogState Chairman appointed honour

Mr Martyn Myer has been appointed an Officer (AO) in the general division of the Order of Australia in the recent Queen's Birthday Honours list.

Mr Myer is Chairman of CogState Limited. Mr Myer also Chairs the Remuneration and Nomination Committee and serves on the Audit and Compliance Committee. Until 30 June 2007 he was President of the Howard Florey Institute of Experimental Physiology and Medicine and he is now a director of the Florey Neuroscience Institutes. At the Howard Florey Institute he has participated in the transition of the Institute’s research focus to diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases.

Whilst President of the Howard Florey Institute, Mr Myer and the Director, Professor Fred Mendelsohn, negotiated the merge of the Institute with the Brain Research Institute and the National Stroke research Institute to create the Florey Neuroscience Institutes. At the same time Mr Myer and Professor Mendelsohn lead the raising of over $170 million towards the $200 million cost of two new neuroscience research buildings, one at the University of Melbourne Parkville campus and the other at the Austin Hospital. At these two new facilities (due to be complete in 2011) the Florey Neuroscience Institutes will be co-located with the Mental Health Research Institute and the majority of the University of Melbourne’s neuroscientists.

Mr Myer has been awarded the honour for service to business and to the community, particularly through contributions to medical research and the establishment of the Florey Neurosciences Institutes and through executive and philanthropic roles with a range of organisations.

About CogState

CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.

Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, AstraZeneca, GlaxoSmithKline, Merck, Abbott Laboratories, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Lundbeck and Organon USA. CogState is currently expanding its existing activities in the US and European clinical trial markets.

For additional information:

Brad O’Connor Chief Executive Officer CogState Ltd. 03 9664 1300 Mob: 0411 888 347

boconnor@cogstate.com

Page 1 of 1